Product Information
RELISTOR 150 MG TABLET is a brand product labeled by Salix Pharmaceuticals Inc., priced at $26.8914 per EA under NDC 65649015090. Its NADAC has been published 438 times since May 17, 2017.
FDA first approved this application on Jul 19, 2016.
Strength
150 mg/1
Manufacturer
Salix Pharmaceuticals Inc.NDC
65649015090
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/17/2025
Active Ingredients
METHYLNALTREXONE BROMIDEApproval Type
New Drug (NDA)
FDA Application
NDA208271FDA Approved
7/19/2016
On Market Since
8/1/2008
Pharmacological Classes
Price Statistics
The NADAC for RELISTOR 150 MG TABLET has been published 438 times since May 17, 2017, and over the history we have for it it has risen 69.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $26.8914 per EA |
|---|---|
| All-time high | $26.9009 (Sep 10, 2025) |
| All-time low | $15.9022 (May 17, 2017) |
| Median price | $21.4665 |
| Average price | $21.5798 |
| Largest weekly change | +9.0% (Oct 11, 2017) |
| Weeks tracked | 438 |
| Tracking since | May 17, 2017 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+8.8%
5Y
+25.3%
All
+69.1%
Last surveyed Oct 1, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Methylnaltrexone bromide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Salix Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylnaltrexone bromide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RELISTOR 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RELISTOR 150 MG TABLET, manufactured by Salix Pharmaceuticals Inc., is $26.8914 per EA (NDC 65649015090), effective Oct 1, 2025.
How has the price of RELISTOR 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for RELISTOR 150 MG TABLET has risen 69.1%. It has been tracked across 438 weekly CMS publications since May 17, 2017.
What are the highest and lowest recorded NADAC prices for RELISTOR 150 MG TABLET?
Since May 17, 2017, the NADAC for RELISTOR 150 MG TABLET has ranged from a low of $15.9022 (May 17, 2017) to a high of $26.9009 (Sep 10, 2025), with a median of $21.4665 per EA.
Are there cheaper alternatives to RELISTOR 150 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of RELISTOR 150 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RELISTOR 150 MG TABLET?
RELISTOR 150 MG TABLET (NDC 65649015090) is labeled by Salix Pharmaceuticals Inc., and CMS classifies it as a brand product.